CytomX Therapeutics, Inc. Forecasted to Earn Q1 2018 Earnings of ($0.21) Per Share (CTMX)
CytomX Therapeutics, Inc. (NASDAQ:CTMX) – Equities researchers at Wedbush issued their Q1 2018 earnings per share estimates for CytomX Therapeutics in a report released on Wednesday. Wedbush analyst R. Driscoll forecasts that the biotechnology company will post earnings per share of ($0.21) for the quarter. Wedbush has a “Outperform” rating and a $37.00 price target on the stock. Wedbush also issued estimates for CytomX Therapeutics’ Q2 2018 earnings at ($0.24) EPS, Q3 2018 earnings at ($0.27) EPS and Q4 2018 earnings at ($0.30) EPS.
CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.30). The company had revenue of $8.75 million for the quarter, compared to the consensus estimate of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/05/cytomx-therapeutics-inc-forecasted-to-earn-q1-2018-earnings-of-0-21-per-share-ctmx.html.
Several other brokerages also recently issued reports on CTMX. Cowen and Company reissued an “outperform” rating on shares of CytomX Therapeutics in a report on Thursday. Nomura lifted their price target on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a report on Wednesday. Bank of America Corporation lifted their price target on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday. Oppenheimer Holdings, Inc. reissued a “hold” rating on shares of CytomX Therapeutics in a report on Wednesday. Finally, ValuEngine downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. CytomX Therapeutics presently has a consensus rating of “Hold” and an average price target of $32.67.
CytomX Therapeutics (NASDAQ:CTMX) traded down 1.56% during midday trading on Thursday, reaching $22.73. 140,583 shares of the company traded hands. The firm’s market capitalization is $837.99 million. The firm’s 50 day moving average price is $16.92 and its 200 day moving average price is $15.62. CytomX Therapeutics has a 12 month low of $9.85 and a 12 month high of $24.67.
Several hedge funds and other institutional investors have recently made changes to their positions in CTMX. Teachers Advisors LLC raised its stake in shares of CytomX Therapeutics by 6.7% in the fourth quarter. Teachers Advisors LLC now owns 34,961 shares of the biotechnology company’s stock worth $384,000 after acquiring an additional 2,209 shares during the last quarter. Strs Ohio bought a new position in shares of CytomX Therapeutics in the first quarter worth about $207,000. Wells Fargo & Company MN raised its stake in shares of CytomX Therapeutics by 52.8% in the first quarter. Wells Fargo & Company MN now owns 22,424 shares of the biotechnology company’s stock worth $387,000 after acquiring an additional 7,747 shares during the last quarter. Swiss National Bank raised its stake in shares of CytomX Therapeutics by 19.1% in the first quarter. Swiss National Bank now owns 26,800 shares of the biotechnology company’s stock worth $463,000 after acquiring an additional 4,300 shares during the last quarter. Finally, Oxford Asset Management raised its stake in shares of CytomX Therapeutics by 28.4% in the first quarter. Oxford Asset Management now owns 31,665 shares of the biotechnology company’s stock worth $547,000 after acquiring an additional 6,995 shares during the last quarter. 59.97% of the stock is owned by institutional investors.
In other CytomX Therapeutics news, major shareholder Robert I. Tepper sold 24,777 shares of the business’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $24.34, for a total value of $603,072.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $15.00, for a total transaction of $37,500.00. Following the completion of the transaction, the chief financial officer now directly owns 19,626 shares of the company’s stock, valued at $294,390. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 100,306 shares of company stock valued at $1,924,746. Insiders own 4.70% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.